BOHOŠOVÁ, Júlia, Jiří VAJČNER, Petr JABANDŽIEV, Hana OŠLEJŠKOVÁ, Ondřej SLABÝ and Štefánia AULICKÁ. MicroRNAs in the development of resistance to antiseizure drugs and their potential as biomarkers in pharmacoresistant epilepsy. Epilepsia. Hoboken: Wiley-Blackwell, 2021, vol. 62, No 11, p. 2573-2588. ISSN 0013-9580. Available from: https://dx.doi.org/10.1111/epi.17063.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name MicroRNAs in the development of resistance to antiseizure drugs and their potential as biomarkers in pharmacoresistant epilepsy
Authors BOHOŠOVÁ, Júlia (703 Slovakia, belonging to the institution), Jiří VAJČNER (203 Czech Republic, belonging to the institution), Petr JABANDŽIEV (203 Czech Republic, belonging to the institution), Hana OŠLEJŠKOVÁ (203 Czech Republic, belonging to the institution), Ondřej SLABÝ (203 Czech Republic, belonging to the institution) and Štefánia AULICKÁ (703 Slovakia, guarantor, belonging to the institution).
Edition Epilepsia, Hoboken, Wiley-Blackwell, 2021, 0013-9580.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30210 Clinical neurology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 6.740
RIV identification code RIV/00216224:14110/21:00120160
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1111/epi.17063
UT WoS 000692515800001
Keywords in English biomarkers; drug-resistant epilepsy; intractable epilepsy; noncoding RNA; refractory epilepsy
Tags 14110317, 14110320, 14110513, podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 28/2/2022 07:22.
Abstract
Although many new antiseizure drugs have been developed in the past decade, approximately 30%-40% of patients remain pharmacoresistant. There are no clinical tools or guidelines for predicting therapeutic response in individual patients, leaving them no choice other than to try all antiseizure drugs available as they suffer debilitating seizures with no relief. The discovery of predictive biomarkers and early identification of pharmacoresistant patients is of the highest priority in this group. MicroRNAs (miRNAs), a class of short noncoding RNAs negatively regulating gene expression, have emerged in recent years in epilepsy, following a broader trend of their exploitation as biomarkers of various complex human diseases. We performed a systematic search of the PubMed database for original research articles focused on miRNA expression level profiling in patients with drug-resistant epilepsy or drug-resistant precilinical models and cell cultures. In this review, we summarize 17 publications concerning miRNAs as potential new biomarkers of resistance to antiseizure drugs and their potential role in the development of drug resistance or epilepsy. Although numerous knowledge gaps need to be filled and reviewed, and articles share some study design pitfalls, several miRNAs dysregulated in brain tissue and blood serum were identified independently by more than one paper. These results suggest a unique opportunity for disease monitoring and personalized therapeutic management in the future.
Links
NU21-04-00305, research and development projectName: Analýza transkriptomu a metylace DNA u pacientů s fokální kortikální dysplázií
Investor: Ministry of Health of the CR, Transcriptomics and DNA methylation analysis in patients with focal cortical dysplasia, Subprogram 1 - standard
PrintDisplayed: 21/7/2024 00:24